SCHEMBL2276321

SCHEMBL2276321

Cc1cccc(C(=O)Nc2cc(-c3cccc(Cl)c3)ccc2C(=O)O)c1C

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.56
PTGER4 P35408 2/20 0.52
PTGER2 P43116 1/20 0.52
SUCNR1 Q9BXA5 1/20 0.51
HCAR2 Q8TDS4 1/20 0.49
GRIK1 P39086 4/20 0.48
DCLRE1B Q9H816 1/20 0.47
SERPINE1 P05121 1/20 0.46
KCNMA1 Q12791 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275722 0.90 ACLY (0.57) ACLYSUCNR1NPC1RAB9A
SCHEMBL14429486 0.86 KCNMA1 (0.44) ACLYPTGER4PTGER2SUCNR1KCNMA1
SCHEMBL2278464 0.85 ACLY (0.49) ACLYSUCNR1HCAR2NPC1RAB9A
SCHEMBL2269657 0.85 ALDH1A1 (0.45) ACLYPTGER4PTGER2KCNMA1NPC1
SCHEMBL27696863 0.83 ACLY (0.62) ACLYSUCNR1HCAR2GRIK1SERPINE1
SCHEMBL2276482 0.81 ACLY (0.74) ACLYSUCNR1GRIK1SERPINE1NPC1
SCHEMBL2268189 0.81 ACLY (0.61) ACLYSUCNR1NPC1RAB9A
SCHEMBL2274223 0.80 ALDH1A1 (0.53) GRIK1NPC1RAB9A
SCHEMBL12117713 0.80 ALDH1A1 (0.50) ACLYNPC1RAB9A
SCHEMBL4209151 0.79 ACLY (0.55) ACLYSUCNR1HCAR2GRIK1DCLRE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885PTGER4 1114/4885PTGER2 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.